Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 0.56 |
| ▸ | ESR1 | P03372 | 8/20 | 0.54 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.44 |
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2358440 | 1.00 | HSD17B1 (0.56) | HSD17B1ESR1ESR2CYP11B1CYP11B2 | |
| SCHEMBL4632528 | 1.00 | HSD17B1 (0.56) | HSD17B1ESR1ESR2CYP11B1CYP11B2 | |
| SCHEMBL13110353 | 0.96 | ESR1 (0.56) | HSD17B1ESR1ESR2CYP11B1CYP11B2 | |
| SCHEMBL12035621 | 0.92 | HSD17B1 (0.61) | HSD17B1ESR1ESR2FFAR1PPARD | |
| SCHEMBL2464209 | 0.92 | HSD17B1 (0.61) | HSD17B1ESR1ESR2FFAR1PPARD | |
| SCHEMBL820900 | 0.92 | HSD17B1 (0.61) | HSD17B1ESR1ESR2FFAR1PPARD | |
| SCHEMBL30515129 | 0.92 | HSD17B1 (0.61) | HSD17B1ESR1ESR2FFAR1PPARD | |
| SCHEMBL15687648 | 0.87 | ESR1 (0.57) | HSD17B1ESR1ESR2FFAR1HTR6 | |
| SCHEMBL1698093 | 0.86 | CYP11B1 (0.44) | HSD17B1ESR1ESR2CYP11B1CYP11B2 | |
| SCHEMBL10202234 | 0.86 | CYP11B1 (0.44) | HSD17B1ESR1ESR2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079467-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME (US) | 2015-11-18 | — | — | EP | disclosed |
| US-8039484-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2011-10-18 | — | — | US | disclosed |
| US-8039484-B2 | Antidiabetic bicyclic compounds | MERCK SHARP & DOHME CORP. (US) | 2011-10-18 | — | — | US | disclosed |
| US-20100105725-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-04-29 | — | — | US | disclosed |
| US-20100105725-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2010-04-29 | — | — | US | disclosed |
| EP-2001844-A2 | BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2008-12-17 | — | — | EP | disclosed |
| WO-2008054675-A2 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK & CO., INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | AMGEN INC. (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007106469-A2 | BICYCLIC CARBOXYLIC ACID DERIVATIVES USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105725-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | GPR119, FFAR2, GPR65 | HSD17B1 832/4885ESR1 1021/4885ESR2 351/4885 |
| US-20070244155-A1 | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders | GOT2, PC, GOT1 | HSD17B1 267/4885ESR1 3492/4885ESR2 1538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.